Shares of ImmuPharma plc (LON:IMM – Get Free Report) were up 15.4% during trading on Friday . The stock traded as high as GBX 4.79 ($0.06) and last traded at GBX 4.50 ($0.06). Approximately 5,421,370 shares were traded during trading, a decline of 75% from the average daily volume of 21,306,619 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Stock Performance
The business’s 50-day moving average is GBX 2.39 and its 200 day moving average is GBX 1.93. The company has a market cap of £20.32 million, a PE ratio of -488.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Which Wall Street Analysts are the Most Accurate?
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
